Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 95mg; metoprolol succinate 95mg; metoprolol succinate 95mg - modified release tablet - 95 mg - active: metoprolol succinate 95mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 95mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 95mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml; granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml - concentrate for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml excipient: citric acid monohydrate nitrogen sodium chloride sodium citrate water for injection - for the prevention & treatment of nausea & vomiting induced by cytotoxic chemotherapy (adults & children)

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone sodium*3.5h2o. eq 1.0793g of ceft. sodium anh or 1g ceftriaxone anh) - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone sodium*3.5h2o. eq 1.0793g of ceft. sodium anh or 1g ceftriaxone anh) - infections caused by pathogens sensitive to ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftriaxone sodium 2.385 g (present as 2.385g ceftriaxone sodium*3.5h2o. eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh) - powder for injection - 2 g - active: ceftriaxone sodium 2.385 g (present as 2.385g ceftriaxone sodium*3.5h2o. eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh) - infections caused by pathogens sensitive to ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftriaxone sodium 596mg (present as 0.596g ceftriaxone sodium*3.5h2o. eq 0.53965g of ceft. sodium anh or 0.5g ceftriaxone anh) - powder for injection - 500 mg - active: ceftriaxone sodium 596mg (present as 0.596g ceftriaxone sodium*3.5h2o. eq 0.53965g of ceft. sodium anh or 0.5g ceftriaxone anh) - infections caused by pathogens sensitive to ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 2.194 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 5.485 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 1.097 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.